Kaliumklorid Noridem (Potassium Chloride)

Potassium chloride delivers potassium ions directly into the bloodstream, raising extracellular potassium concentration. This restores the normal electrochemical gradient needed for nerve impulse transmission, muscle contraction, and stable cardiac rhythm, thereby correcting the physiological disturbances of hypokalemia.

The dose of Kaliumklorid Noridem is individualized by the prescribing clinician based on the patient’s serum potassium level, renal function, and overall clinical status. The healthcare professional determines the appropriate concentration, infusion rate, and total amount required.

Safety in pregnancy and lactation has not been fully established. It should be used only when clearly needed, after a careful risk‑benefit assessment by the treating physician, and with close monitoring of maternal potassium levels.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Kaliumklorid Noridem is an injectable form, allowing rapid correction of severe hypokalemia, whereas oral potassium salts provide slower, less controlled repletion. Intravenous administration is preferred in acute settings, intensive care, or when oral intake is not feasible.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use to maintain sterility and potency.

Kaliumklorid Noridem is given by intravenous infusion under medical supervision. The infusion rate is calculated based on the patient’s potassium deficit, renal function, and cardiac status, and the patient is monitored for signs of hyper‑ or hypokalemia during administration.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias or cardiac arrest, and extravasation leading to tissue necrosis. Prompt monitoring of serum potassium and cardiac rhythm is essential to mitigate these risks.

Patients with severe renal failure, untreated hyperkalemia, or known hypersensitivity to potassium chloride should not receive Kaliumklorid Noridem. It is also contraindicated in individuals taking multiple potassium‑raising agents without appropriate monitoring.